The primates in the trial achieved the improved glycemic control after treatment with MicroIslet’s proprietary microencapsulated porcine islet transplantation treatment approach. Primates in the trial showed substantial reduction in the need for insulin to control blood glucose levels.
Additionally, this breakthrough was achieved without the need for chronic immunosuppressive therapy to prevent rejection of the transplanted insulin-producing islets.
According to MicroIslet, this six-month milestone represents an “industry first in the effort to establish a more effective treatment for diabetes.”
“We believe that with this positive data, we are setting the cornerstone for a new and vastly improved treatment for diabetes, which has reached an epidemic stage, afflicting an estimated 21 million Americans, including over six million who are undiagnosed,” commented Dr James Gavin, president and CEO of MicroIslet.